Featured Publications
Stay current with the featured publications
The Journal of Clinical Investigation 2018
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG
The Journal of Clinical Investigation 2021
Latest Publications
Stay current with the latest journal articles and featured publications
| Year | Title | Authors | Journal/Book |
|---|---|---|---|
| 2016 | Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia | Haffner MC, Barbieri CE. | Eur Urol |
| 2014 | SPOP mutations in prostate cancer across demographically diverse patient cohorts | Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA. | Neoplasia |
| 2014 | TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia | Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA. | J Clin Oncol |
| 2014 | Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment | Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. | Cancer Epidemiol Biomarkers Prev |
| 2014 | Molecular characterization of prostate cancer following androgen deprivation: the devil in the details | Barbieri CE, Rubin MA. | Eur Urol |
| 2014 | Unraveling the clonal hierarchy of somatic genomic aberrations | Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. | Genome Biol |
| 2014 | The lethal clone in prostate cancer: redefining the index | Barbieri CE, Demichelis F, Rubin MA. | Eur Urol |
| 2014 | Evidence for molecular differences in prostate cancer between African American and Caucasian men | Khani F, Mosquera JM, Park K, Blattner M, O'Reilly C, MacDonald TY, Chen Z, Srivastava A, Tewari AK, Barbieri CE, Rubin MA, Robinson BD. | Clin Cancer Res |
| 2013 | Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover | Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades N. | Proc Natl Acad Sci U S A |
| 2013 | Punctuated evolution of prostate cancer genomes | Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. | Cell |
| 2014 | The prostate cancer genome: perspectives and potential | Barbieri CE, Tomlins SA. | Urol Oncol |
| 2015 | The Molecular Taxonomy of Primary Prostate Cancer | Cancer Genome Atlas Research Network. | Cell |
| 2016 | Molecular subtyping of prostate cancer | Kaffenberger SD, Barbieri CE. | Curr Opin Urol |
| 2016 | Clinical variability and molecular heterogeneity in prostate cancer | Shoag J, Barbieri CE. | Asian J Androl |
| 2016 | Lethal Prostate Cancer in the PLCO Cancer Screening Trial | Shoag J, Mittal S, Halpern JA, Scherr D, Hu JC, Barbieri CE. | Eur Urol |
| 2016 | Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing | Shoag J, Halpern JA, Lee DJ, Mittal S, Ballman KV, Barbieri CE, Hu JC. | J Urol |
| 2015 | Genomic rearrangements in prostate cancer | Barbieri CE, Rubin MA. | Curr Opin Urol |
| 2015 | Reprint of: The prostate cancer genome: Perspectives and potential | Barbieri CE, Tomlins SA. | Urol Oncol |
| 2015 | Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting | Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, Pienta KJ, Soule HR. | Prostate |
| 2015 | SPOP mutation leads to genomic instability in prostate cancer | Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, Sboner A, de Bono JS, Demichelis F, Houvras Y, Rubin MA. | Elife |
| 2015 | Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial | Shoag J, Halpern J, Eisner B, Lee R, Mittal S, Barbieri CE, Shoag D. | JAMA Oncol |
| 2013 | Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456 | Barbieri CE, Sboner A, Rubin MA, Garraway LA. | J Pathol |
| 2013 | The mutational landscape of prostate cancer | Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA. | Eur Urol |
| 2006 | p63 and epithelial biology | Barbieri CE, Pietenpol JA. | Exp Cell Res |
| 2006 | The DNA binding activity of p53 displays reaction-diffusion kinetics | Hinow P, Rogers CE, Barbieri CE, Pietenpol JA, Kenworthy AK, DiBenedetto E. | Biophys J |
| 2006 | Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis | Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. | Cancer Res |
| 2005 | IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium | Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. | Cancer Res |
| 2005 | p53 family members: similar biochemistry, different biology | Barbieri CE, Pietenpol JA. | Cancer Biol Ther |
| 2005 | Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha | Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. | Cell Cycle |
| 2003 | Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells | Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. | Laryngoscope |
| 2003 | Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway | Barbieri CE, Barton CE, Pietenpol JA. | J Biol Chem |
| 2022 | Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci | Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CE, Mosquera JM. | JCI Insight |
| 2007 | Association of procedure volume with radical cystectomy outcomes in a nationwide database | Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA Jr, Chang SS. | J Urol |
| 2009 | DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis | Barton CE, Tahinci E, Barbieri CE, Johnson KN, Hanson AJ, Jernigan KK, Chen TW, Lee E, Pietenpol JA. | Dev Biol |
| 2013 | Evolution of novel biomarkers for detection of prostate cancer | Barbieri CE. | J Urol |
| 2012 | Molecular genetics of prostate cancer: emerging appreciation of genetic complexity | Barbieri CE, Demichelis F, Rubin MA. | Histopathology |
| 2012 | Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial | Barbieri CE, Cha EK, Chromecki TF, Dunning A, Lotan Y, Svatek RS, Scherr DS, Karakiewicz PI, Sun M, Mazumdar M, Shariat SF. | BJU Int |
| 2012 | Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. | Nat Genet |
| 2012 | Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium | Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ Jr, Abraham C, Banerjee S, Leung RA, Tewari AK, Terry S, Shevchuk MM, Rickman DS, Rubin MA; Weill Cornell Medical College. | Diagn Mol Pathol |
| 2012 | Deletion or underexpression of the Y-chromosome genes CDY2 and HSFY is associated with maturation arrest in American men with nonobstructive azoospermia | Stahl PJ, Mielnik AN, Barbieri CE, Schlegel PN, Paduch DA. | Asian J Androl |
| 2011 | Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner | Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT. | J Urol |
| 2010 | Tissue-based molecular markers for bladder cancer | Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, Shariat SF. | Minerva Urol Nefrol |
| 2010 | Ureteroileal anastomosis with intraluminal visualization: technique and outcomes | Barbieri CE, Schwartz MJ, Boorjian SA, Lee MM, Scherr DS. | Urology |
| 2022 | Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130 | Kwon OJ, Zhang B, Jia D, Zhang L, Wei X, Zhou Z, Liu D, Huynh KT, Zhang K, Zhang Y, Labhart P, Sboner A, Barbieri C, Haffner MC, Creighton CJ, Xin L. | Oncogene |
| 2021 | G3BP1 inhibits Cul3(SPOP) to amplify AR signaling and promote prostate cancer | Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LD, Cyrta J, Davicioni E, Sboner A, Robinson BD, Chinnaiyan AM, Rubin MA, Barbieri CE, Zhou P. | Nat Commun |
| 2020 | Prognostic value of the SPOP mutant genomic subclass in prostate cancer | Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E, Karnes J, Den RB, Liu Y, Davicioni E, Barbieri CE. | Urol Oncol |
| 2020 | Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes | Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, Lee R, Chughtai B, Olumi AF, Mosquera JM, Demichelis F, Elemento O, Rubin MA, Sboner A, Barbieri CE. | Nat Commun |
| 2020 | Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States | Mahase SS, D'Angelo D, Kang J, Hu JC, Barbieri CE, Nagar H. | JAMA Netw Open |
| 2020 | Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma | van der Mijn JC, Fu L, Khani F, Zhang T, Molina AM, Barbieri CE, Chen Q, Gross SS, Gudas LJ, Nanus DM. | Transl Oncol |
| 2019 | Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations | Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL. | J Pathol |
| 2019 | N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer | Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS. | J Clin Invest |
| 2019 | FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes | Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL. | Nature |
| 2019 | Publisher Correction: The long tail of oncogenic drivers in prostate cancer | Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM. | Nat Genet |
| 2019 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer | Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H. | JCO Precis Oncol |
| 2020 | Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US | Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. | JAMA Netw Open |
| 2020 | Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes | Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL. | Nature |
| 2021 | Race and Genetic Alterations in Prostate Cancer | Schumacher FR, Basourakos SP, Lewicki PJ, Vince R, Spratt DE, Barbieri CE, Shoag JE. | JCO Precis Oncol |
| 2021 | Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity | Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, Lin K, Ivenitsky D, Goueli R, Robinson BD, Khani F, Deonarine LD, Blattner M, Elemento O, Davicioni E, Sboner A, Barbieri CE. | Cell Rep |
| 2021 | Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study | Balasubramanian A, Nagar H, Barbieri CE, Tagawa ST, McClure TD. | J Vasc Interv Radiol |
| 2021 | Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts | Cai PY, Ma X, Christos P, Barbieri CE, Shoag JE. | J Urol |
| 2021 | Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer | Basourakos SP, Tzeng M, Lewicki PJ, Patel K, Awamlh BAHA, Venkat S, Shoag JE, Gorin MA, Barbieri CE, Hu JC. | Front Oncol |
| 2021 | Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer | Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, Karnes RJ, Trock BJ, Klein EA, Den RB, Demichelis F, Davicioni E, Sboner A, Barbieri CE. | J Clin Invest |
| 2021 | Active Surveillance for Men with Intermediate Risk Prostate Cancer | Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. | J Urol |
| 2020 | Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes | Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, Liu S, Heemers HV. | Eur Urol Open Sci |
| 2020 | CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable? | Marciscano AE, Barbieri CE. | Eur Urol |
| 2019 | CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis | Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y, Rubin MA, Beltran H, Elemento O, Bergman AM, Zwart W, Sboner A, Dephoure N, Barbieri CE. | Cancer Cell |
| 2019 | Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility | Shoag JE, Tosoian JJ, Salami SS, Barbieri CE. | Eur Urol |
| 2017 | DNA Repair in Prostate Cancer: Biology and Clinical Implications | Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. | Eur Urol |
| 2017 | SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling | Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V, Ponnala L, Ittmann M, Chinnaiyan AM, Sboner A, Chen Y, Rubin MA, Barbieri CE. | Cancer Cell |
| 2017 | Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial | Lewicki P, Shoag J, Golombos DM, Oromendia C, Ballman KV, Halpern JA, Stone BV, O'Malley P, Barbieri CE, Scherr DS. | J Urol |
| 2016 | Editorial Comment | Barbieri CE. | J Urol |
| 2017 | Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations | Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. | Genome Biol |
| 2017 | Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics | Wang H, Barbieri CE, He J, Gao Y, Shi T, Wu C, Schepmoes AA, Fillmore TL, Chae SS, Huang D, Mosquera JM, Qian WJ, Smith RD, Srivastava S, Kagan J, Camp DG 2nd, Rodland KD, Rubin MA, Liu T. | J Transl Med |
| 2017 | Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 | Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W. | Nat Med |
| 2017 | Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition | Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, Abate-Shen C. | Eur Urol |
| 2017 | Vasectomy and Risk of Prostate Cancer in a Screening Trial | Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, Hu JC, Scherr D, Schlegel P, Barbieri CE. | Cancer Epidemiol Biomarkers Prev |
| 2017 | The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics | Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. | Eur Urol |
| 2017 | Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men | Stone BV, Shoag J, Halpern JA, Mittal S, Lewicki P, Golombos DM, Bedretdinova D, Chughtai B, Barbieri CE, Lee RK. | BJU Int |
| 2019 | The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer | Gaffney C, Golan R, Cantu MD, Scognamiglio T, McCarthy H, Mosquera JM, McClure TD, Barbieri CE, Robinson BD, Khani F. | J Urol |
| 2018 | The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study | Golombos DM, Ayangbesan A, O'Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, Scherr DS. | Urology |
| 2018 | Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer | Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE. | JCO Precis Oncol |
| 2018 | SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG | Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JM, Chen Y, Rubin MA, Barbieri CE. | J Clin Invest |
| 2018 | The long tail of oncogenic drivers in prostate cancer | Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM. | Nat Genet |
| 2018 | Molecular Subtypes of Prostate Cancer | Arora K, Barbieri CE. | Curr Oncol Rep |
| 2018 | Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy" | Barbieri CE. | Urol Oncol |
| 2018 | Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates | Golan R, Patel NA, Sun T, Barbieri CE, Sedrakyan A, Kashanian JA. | J Sex Med |
| 2018 | SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity | Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira FM, Atkin M, Clarke M, Goodall J, Sharp A, MacDonald T, Rubin MA, Yuan W, Barbieri CE, Carreira S, Mateo J, de Bono JS. | Clin Cancer Res |
| 2017 | Molecular alterations in prostate cancer and association with MRI features | Lee D, Fontugne J, Gumpeni N, Park K, MacDonald TY, Robinson BD, Sboner A, Rubin MA, Mosquera JM, Barbieri CE. | Prostate Cancer Prostatic Dis |
